Drug intelligence / Profile preview

HS-10515

Development stage: Preclinical
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules

Overview

**HS-10515** is a small molecule inhibitor of Werner (WRN) helicase, a RecQ family DNA helicase essential for DNA repair and replication. It demonstrates robust inhibition of WRN enzymatic activity, leading to synthetic lethality in microsatellite instability-high (MSI-H) cancer cells, which depend on WRN for survival due to defective mismatch repair. Preclinical data show strong anti-proliferative effects across a panel of MSI-H cancer cell lines, positioning it as a targeted therapy for MSI-H tumors, such as colorectal cancers, with potential for clinical advancement.[1]

Targets

WRN (Werner syndrome ATP-dependent helicase)

Beyond the preview

Go deeper on HS-10515.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10515.

Explore the full profile